XML 31 R20.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements and Short-Term Investments (Tables)
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Debt Securities, Available-for-sale
The following is a summary of the Company’s short-term investments, considered available-for-sale, as of March 31, 2019 (in thousands):
 
Amortized
 
Gross Unrealized
 
Estimated
 
Cost
 
Gains
 
Losses
 
Fair Value
Available-for-sale securities
 
 
 
 
 
 
 
U.S treasury securities
$
79,321

 
$

 
$
(8
)
 
$
79,313

Schedule of financial instruments recorded at fair value on a recurring basis
The following table (in thousands) shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable to a related party for the three months ended March 31, 2019:
 
March 31, 2019
Fair value, beginning of period
$
50,200

FDA milestone payment
(9,213
)
Change in fair value recorded in operating expenses
4,913

Fair value, end of period
$
45,900

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The fair value of these instruments was as follows (in thousands):
 
As of March 31, 2019
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
Available-for-sale securities
 
 
 
 
 
 
 
U.S treasury securities
$
79,313

 
$
79,313

 
$

 
$

Liabilities
 
 
 
 
 
 
 
Contingent royalty obligation payable to Evolus Founders, a related party
$
45,900

 
$

 
$

 
$
45,900

 
As of December 31, 2018
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
Liabilities
 
 
 
 
 
 
 
Contingent royalty obligation payable to Evolus Founders, a related party
$
50,200

 
$

 
$

 
$
50,200